373 related articles for article (PubMed ID: 16507216)
21. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
22. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
23. Novel drugs for renal cell carcinoma.
Vakkalanka BK; Bukowski RM
Expert Opin Investig Drugs; 2008 Oct; 17(10):1501-16. PubMed ID: 18808310
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
25. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
26. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
27. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
28. Molecular targeting therapy for renal cell carcinoma.
Eto M; Naito S
Int J Clin Oncol; 2006 Jun; 11(3):209-13. PubMed ID: 16850127
[TBL] [Abstract][Full Text] [Related]
29. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Desai AA; Stadler WM
Curr Oncol Rep; 2005 Mar; 7(2):116-22. PubMed ID: 15717945
[TBL] [Abstract][Full Text] [Related]
30. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
31. Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Linassier C; Carmier D; Combe P; D'Arcier BF; Bruyere F; Narciso B
Anticancer Res; 2012 Feb; 32(2):697-700. PubMed ID: 22287765
[TBL] [Abstract][Full Text] [Related]
32. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
33. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
34. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
35. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
36. Treatment options in renal cell carcinoma: past, present and future.
Oudard S; George D; Medioni J; Motzer R
Ann Oncol; 2007 Sep; 18 Suppl 10():x25-31. PubMed ID: 17761720
[TBL] [Abstract][Full Text] [Related]
37. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
Cho DC; Puzanov I; Regan MM; Schwarzberg T; Seery V; Lee MY; Liu V; Bhatt R; Koon H; Mier JW; Sosman JA; Atkins MB; McDermott DF
J Immunother; 2009; 32(2):181-5. PubMed ID: 19238017
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy for metastatic renal cell carcinoma.
Patel PH; Chaganti RS; Motzer RJ
Br J Cancer; 2006 Mar; 94(5):614-9. PubMed ID: 16465192
[TBL] [Abstract][Full Text] [Related]
40. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]